Press Release

MOLOGEN AG: Important Technology Patent Granted for the USA

Berlin, 2005-03-17

MOLOGEN AG yesterday received the granting certificate for their dSLIM technology patent from the US Patent and Trademark Office (Patent No.: 6,849,725 B2).

With the basic dSLIM patent now granted for the US MOLOGEN has reached an important milestone in their current development and marketing strategy. The European Patent Agency had already granted the first dSLIM patent back in January 2004. Future drugs and vaccines on the basis of dSLIM will be protected in the US until 2020.

Alongside MIDGE, dSLIM is the second key technology of MOLOGEN. Contained in the dSLIM patent protection is a covalently closed nucleic acid molecule for immune modulation. The immune modulation is based on a DNA structure that is represented by specific sequence symmetries and sequence motives.


Trademark dSLIM about to be registered

dSLIM Patents will be additionally and complimentary supported by the shortly expected international registration of the dSLIM trademark. International trademark protection is of high importance in those countries, which have not yet signed the international patent treaty, but where MOLOGEN negotiates and closes significant deals.


Immunological mode of action of dSLIM

The human immune system has three different modes of action, which are connected with each other. By application of an immune modulator, the most efficacious mode of action can be triggered and enhanced.

dSLIM forms the basis for further developments in augmenting and controlling preventive and therapeutic immune reactions by immune modulation against malignant diseases and serious infections. dSLIM has already been successfully tested in a phase IIa clinical trial in the treatment of metastatic intestinal cancer. In combination with MIDGE-modified tumour cells, dSLIM is a component in a cell-based tumour therapy that was successfully tested in a phase Ib/II clinical trial. Trials using dSLIM to protect against aggressive infections are currently taking place and are being evaluated by international partners.



MOLOGEN uses its proprietary DNA technologies to create and develop treatments for high-unmet-need illnesses. The main focus are the unique and patented MIDGE and dSLIM technologies. Based on these platforms, MOLOGEN is developing DNA-based vaccines and therapeutics to prevent or cure a wide range of diseases.

Going public in 1998, MOLOGEN was one of the first German biotechnology companies to be floated on the stock exchange. The MOLOGEN shares are traded on the Geregelter Markt in Frankfurt.


Contact: Matthias Reichel
Phone: +49-30-84 17 88 - 0
Fax: +49-30-84 17 88 - 50
e-mail: [email protected]